

Supplementary Table S3. Grade ≥ 3 adverse events of special interest by treatment arm occurring between 18 months after the first dose of study drug and the end of the study

Adverse event of special interest	Chemotherapy alone (<i>N</i> = 1271)	Chemotherapy + bevacizumab (<i>N</i> = 1288)
Any event, <i>N</i> (%)	9 (0.7)	9 (0.7)
Arterial thromboembolic event, <i>N</i> (%)	1 (0.1) ^a	5 (0.4) ^b
Venous thromboembolic event, <i>N</i> (%)	3 (0.2) ^c	0
Bleeding, <i>N</i> (%)	1 (0.1) ^d	3 (0.2) ^e
Congestive heart failure, <i>N</i> (%)	0	1 (0.1) ^f
Hypertension, <i>N</i> (%)	4 (0.3) ^g	0
Proteinuria, <i>N</i> (%)	0	0
Wound-healing complication, <i>N</i> (%)	0	2 (0.2) ^h
RPLS, <i>N</i> (%)	0	0

Gastrointestinal perforation, <i>N</i> (%)	0	0
Fistula/abscess, <i>N</i> (%)	0	0
Febrile neutropenia, <i>N</i> (%)	0	0

^aGrade 3 myocardial infarction.

^bGrade 3 myocardial infarction (*N* = 1), grade 4 myocardial infarction (*N* = 1), grade 4 acute myocardial infarction (*N* = 1), grade 5 cerebrovascular accident (*N* = 1; the same event is also reported within the category 'Bleeding'), grade 3 transient ischemic attack (*N* = 1).

^cGrade 3 deep vein thrombosis (*N* = 3).

^dGrade 3 dysfunctional uterine bleeding.

^eGrade 5 cerebrovascular accident (*N* = 1; the same event is also reported within the category 'Arterial thromboembolic event'), grade 2/3 diverticulitis intestinal hemorrhagic (*N* = 1; repeated grade 2 and one grade 3 episode, attributed to ongoing colonic diverticulitis), grade 4 hematoma (*N* = 1).

^fGrade 3 cardiac failure congestive.

^gGrade 3 hypertension (*N* = 4)

^hGrade 3 wound caused by a traffic accident (*N* = 1), grade 3 wound abscess (*N* = 1).

In each patient, the adverse event occurred before any reported IDFS event, or in the case of the grade 5 cerebrovascular event, was itself the IDFS event.

IDFS, invasive disease-free survival; RPLS, **reversible posterior**
leukoencephalopathy syndrome.
